HCRx is focused on providing non-dilutive, structured financing solutions to late stage and commercial-stage life sciences companies.  As an alternative or complement to an equity issuance, our funding allows a company to eliminate or delay dilution while enabling the company to fund product launches, acquire or license products, or re-invest capital in earlier-stage R&D projects.

HCRx has the flexibility to provide a broad range of financing and structural alternatives to meet the needs of our partners.  We have been specializing in non-dilutive structured financing transactions for more than a decade.

What differentiates HCRx from others in the industry is our team, our experience, our creativity and our flexibility.  We seek to employ time tested principles and deep domain experience to tailor each transaction to the specific needs of our counterparty. We seek to not only provide capital but also to be a long-term partner with the companies in which we invest. There are two broad categories of corporate financing transactions or strategies that we employ:

Structured Credit generally refers to a debt-like corporate financing that has some defined fixed repayment of interest and principal.  HCRx seeks to work with counterparties to structure repayment in a way that meets the company’s financial objectives.             

Royalty-based financing involves a corporate financing where the repayment is typically variable and linked to product sales or company revenue.  When repayment of the financing is tied to product sales, this type of financing aligns our investment with the performance of the product.